natgillin/translations-raw huggingface dataset:
A pharmaceutical composition comprising the compound, the pharmaceutically acceptable salt thereof according to claim 1 and one or more therapeutically active substances selected from TNF-ainhibitors, COX-1/COX-2 inhibitors, COX-2 inhibitors, glucocorticoids, inactivated antibodies for interleukin, regulators for chemotactic factor receptors, antagonists for histamine H1 receptors/antihistamines, leukotriene antagonists, LTD4 antagonists, VLA-4 antagonists, corticosteroids, corticosteroids analogues, B2-agonists, theophylline, leukotriene biosynhetic inhibitors, phosphodiesterase type IV inhibitors, opioids analgesics, anticoagulants, B-blocking agents, B-adrenergic agonists, angiotensin converting enzyme inhibitors or HMG-CoA reductase inhibitors. 
Farmaceutski pripravak, naznačen time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1-4 i jednu ili više terapeutski aktivnih tvari odabranih iz skupa koji čine inhibitori TNF-a, inhibitori COX-1/COX-2, inhibitori COX-2, glukokortikoidi, inaktivirana protutijela za interleukin, regulatori za receptore kemotaktičkog faktora, antagonisti histaminskih HI receptora/antihistaminika, antagonisti leukotriena, antagonisti LTD4, antagonisti VLA-4, kortikosteroidi, analozi kortikosteroida, B2-agonisti, teofilin, biosintetski inhibitori leukotriena, inhibitori fosfodiesteraze tipa IV, opioidni analgetici, antikoagulanti, B fB-blokatori, B-adrenergički agonisti, inhibitori angiotenzin konvertirajućeg enzima ili inhibitori HMG-CoA reduktaze.
R1, R2, R3, R4, and R5 are selected independently from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tertiary butyl; 
R1, R2, R3, R4 1 R5 su odabrani neovisno od sljedećih: vodik, metil, etil, propil, izopropil, butil, izobutil, tercijarni butil;
In particular, the first aggregation level 4 candidate 1102 is mapped on the last physical resource block of the first resource block group and on all physical resource blocks of the second resource block group. 
Naprava za prijem sukaldno jednom od zahtjeva od 5 do 7, naznačena time da je prva vrijednost razine agregacije 21 da je druga vrijednost razine agregacije 4 ili 6.
A compound selected from the group consisting of the following compounds: 
Spoj prema Zahtjevu 1, koje se bira iz grupe koju čine slijedeći spojevi:
at least one of the three CDRs of the VL domain comprises the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, optionally wherein the three CDRs of the VL domain comprise the amino acid sequences of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15. The isolated monoclonal antibody or antigen-binding fragment of claim 1 or claim 2, wherein: the amino acid sequence of the VH domain is at least 90% identical to SEQ ID NO: 3 or SEQ ID NO: 7, optionally wherein the amino acid sequence of the VH domain comprises SEQ ID NO: 3 or SEQ ID NO: 7; and/or 
Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time, da je aminokiselinska sekvenca od VH domene najmanje 90% identična sa SEQ ID NO: 3 ili SEQ ID NO: 7, dok prema potrebi aminokiselinska sekvenca od VH domene sadrži SEQ ID NO: 3 i SEQ ID NO: 7; i/ili je aminokiselinska sekvenca od VL domene najmanje 90% identična sa SEQ ID NO: 5 ili SEQ ID NO: 9, dok prema potrebi aminokiselinska sekvenca od VL domene sadrži SEQ ID NO: 5 i SEQ ID NO: 9.
The mixture was refluxed for 21 hours then the methanol was evaporated to leave an oil which was dissolved in acetic acid (1000 ml). 
Smjesa se refluksira 21 sat i tada se metanol ispari tako da zaostaje ulje koje se otopi u octenoj kiselini (1000 ml).
The process of any one of claims 1 to 11, wherein the curing step c) takes place in an oven with an inside temperature. The process of claim 12, wherein the temperature of step c) is the target inside temperature of the oven and wherein the curing step starts when the inside temperature of the oven reaches said temperature, and the curing step ends either when the heating is stopped or at least reduced and the inside temperature of the oven subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the inside temperature of the oven drops below said temperature in a parabolic or triangular temperature profile. 
Postupak prema bilo kojem zahtjevu od 1 do 11, naznačen time da se korak stvrdnjavanja c) odvija u peći s unutarnjom temperaturom, Postupak prema zahtjevu 12, naznačen time da je temperatura koraka c) ciljana unutarnja temperatura peći i gdje korak stvrdnjavanja počinje nakon što unutarnja temperatura peći dostigne navedenu temperaturu, i korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada se barem reducira te unutarnja temperatura peći nakon toga pada ispod navedene temperature za više od oko 10?C ili ispod oko 62 *C, u temperaturnom profilu nalik platou ili kada unutarnja temperatura peći pada ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
The compound of claim 1 or a salt, isomer or polymorph thereof selected from: 
Spoj u skladu sa zahtjevom 1 ili njegova sol, izomer ili polimorf, naznačen time, da je izabran iz skupine:
The conditions which may be used are given in the chemical examples that follow. 
Radni uvjeti dani su u kemijskim primjerima. NH .
a compound represented by the formula (II): 
Spoj predstavljen formulom (II):
a heavy chain variable region comprising a HCDR1, a HCDR2 and a HCDR3 as shown in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively The PD-1 antibody or the antigen-binding fragment thereof according to claim 1, wherein the antibody or the antigen-binding fragment thereof is a chimeric antibody. 
3, SEKID BR: 4 i SEK ID BR: 5, sukladno opisanom redoslijedu PD-1 protutijelo ili njegov fragment koji se veže na antigen sukladno patentnom zahtjevu 1, pri čemu je to protutijelo ili njegov fragment koji se veže na antigen kimerno protutijelo.
Package comprising portions of fish in the solid form (10), cooked during heat sterilization in an autoclave, characterized in that it is made according to the process according to anyone of the claims 1 to 5. 
Pakiranje koje obuhvaća porcije Tribe u čvrstom obliku (10), kuhane tijekom sterilizacije toplinom u autoklavu, naznačeno time što je načinjeno sukladno postupku sukladno bilo kojem od zahtjeva 1 do 5.
A sealable container according to embodiment 7, wherein the distance between the upper surface of the denesting area and the base of the tray is shorter than the distance between the upper surface of the flange and the base. 
Posuda prema patentnom zahtjevu 7, pri čemu je razmak između gornje površine zone za odvajanje 1 osnove posude manji od razmaka između gornje površine prirubnice i osnove.
This reaction is nearly quantitative. 
Ta reakcija je gotovo kvantitativna.
The gene construction according to claim 3, wherein the vector is an adeno-associated vector. 
Genski konstrukt u skladu s patentnim zahtjevom 3, naznačen time što je vektor adenoasocirani vektor.
-C(O)-heterocyclyl, wherein the heterocyclyl is selected from morpholin-4-yl, pyrrolidin-1-yl and piperidin-1-yl, optionally substituted with one or two groups selected from-F and-OH; and R3 is H or C1-3alkyl optionally substituted with -OH; or a salt or a stereoisomer thereof. 
C(O)-heterociklil, gdje je heterociklil odabran od morfolin-4-ila, pirolidin-1-ila i piperidin-1-ila, opcionalno supstituiranih s jednom ili dvije skupine odabrane od –F i –OH; i je H ili C1-3alkil opcionalno supstituiran s -OH; ili njegova sol ili njegov stereoizomer.
A computer-readable medium having computer executable instructions for a computer system, the instructions being adapted to cause the computer system to perform the method of claim 13. 
Računalno čitljiv medij koji ima računalno izvršive naredbe za računalni sustav, te su naredbe prilagođene tako da uzrokuju da računalni sustav provodi postupak prema zahtjevu11.
Step b) requires the removal of the ester protecting group R1 and of the hydroxy protecting groups R2 in the presence of a mineral base to form the GalNAc acid salt of formula V. 
: ai gdje su R' i Rin kao prethodno navedeno; b) uklanjanje esterske zaštitne skupine R' i hidroksi zaštitne skupine R* u prisutnosti mineralne baze, kako bi se dobila kiselinska sol GalNAc formule V
Composition according to any one of claims 1 to 7, wherein the average particle size of the particles of the complex of the active agent with the ion-exchange resin is 10 to 3000 µm, particularly 30 to 2000 µm and most preferably 50 to 1000 µm, and/or the average particle size of the coated particles is 20 to 5000 µm, particularly 50 to 4000 µm and most preferably 70 to 3000 µm, and/or the coated particles have a specific gravity in the range from 1.1 to 2.0 and preferably from 1.2 to 1.8, and/or the coated particles exhibit a specific surface area in the range of from 1 to 200 m2/g. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time,da prosječna veličina čestice od čestica u kompleksu djelatne tvari sa smolom ionske izmjene, iznosi 10 do 3000 um, posebno 30 do 2000 um i najpoželjnije 50 do 1000 um, i/ili prosječna veličina čestice od obloženih čestica iznosi 20 do 5000 um, posebno 50 do 4000 um i najpoželjnije 70 do 3000 um, i/ili obložene čestice imaju specifičnu težinu u rasponu od 1,1 do 2,0 i poželjno od 1,2 do 1,8, i/ili obložene čestice posjeduju specifično površinsko područje u rasponu od 1 do 200 m2/g.
In one aspect, the animal is a mouse. Thus, the endogenous MHC I locus may be selected from a group consisting of H-2K, H-2D, and H-2L locus. 
Nukleinska kiselina prema zahtjevu 2, naznačena time, da druga sekvenca nukleinske kiseline kodira transmembranske i citoplazmatske domene mišjeg MHC-I-polipeptida, pri čemu mišji MHC-I-polipeptid je opcionalno odabran iz skupine koja se sastoji od H-2K, H-2D i H-2L.
A soft chewable composition according to any preceding claim wherein the filler is present in a concentration of about 10% to about 40% (w/w). 
Mekani veterinarski pripravak za žvakanje prema zahtjevu 24, naznačen time, da: punilo je kombinacija kukuruznog škroba i usitnjenih sojinih proteina i nalazi se u koncentraciji od oko 30% do oko 50% (masa/masa);
a decrease from baseline in Investigator's Global Assessment (IGA) score of at least 25%; 
(D) smanjenje rezultata prema Globalnoj procjeni ispitivača (IGA) za najmanje 25 % u odnosu na osnovicu;
The process of claim 22 wherein the amount of phase-transfer catalyst is 0.1 to 1 mole per mole of 4-hydroxybenzaldehyde. 
Postupak kao što je u patentnom zahtjevu 29, naznačeno time da je količina katalizatora faznog prijenosa 0.1 do 1 mol po molu 4-hidroksibenzaldehida.
Packing unit according to claim 13, characterized in that the copolymer or polymer is a substance from the plastic group of the polyethylene, polypropylene, polyamide, polystyrene or acrylonitrile-butadiene-styrene type. 
Jedinica za pakiranje prema zahtjevu 13, naznačena time da je taj kopolimer ili polimer neka tvar iz plastične skupine tipa polietilena, polipropilena, poliamida, polistirena ili akrilonitril-butadien stirena.
The 16th item relates to a floor panel according to any of the preceding items, characterized in that the insert consists of a strip of synthetic material. 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se umetak sastoji od trake sintetičkog materijala.
The in-line rolling-mill 11 consists of one or more stands for reaching the desired final thickness; for example the stands have been represented in FIG. 
Valjaonica 11, uključena u proizvodnu liniju, sastoji se od jednog ili više stanova kako bi se postigla željena konačna debljina; npr.
A dosage form comprising a therapeutically effective amount of trans-(±)-A9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable carrier for use as a medicament. 
Oblik doziranja koji sadrži terapeutski učinkovitu količinu trans-(±)-A9-tetrahidrokanabinola u kristalnom obliku i farmaceutski prihvatljivog nosača za upotrebu kao lijek.
said first polypeptide chain comprises an amino terminus and a carboxy terminus and from N-terminus to C-terminus: 
(D navedeni prvi polipeptidni lanac sadrži amino terminus i karboksi terminus i od N-terminusa do C- terminusa:
The method of claim 5, wherein the furosemide is administered in a dosage between 0.5 to 5 milligrams of furosemide per kilogram of the feline's bodyweight once or twice daily. 
Pimobendan za uporabu u postupku prema zahtjevu 5, naznačen time, da se furosemid primjenjuje u dozi od 0,5 do 5 ug/kg tjelesne mase jednom dnevno ili dva puta dnevno.
Such a composite material finds uses including the use as a filler in paper. 
Uporaba kompozitnog materijala prema zahtjevu 26 naznačena time da se koristi kao punilo za papir.
reacting the compound of Formula 3A with an electrophile to form a compound of Formula 4A: 
HR P20190096 T1 4) - Reakcija spoja sukladno Formuli 3A s elektrofilom da bi se stvorio spoj sukladno Formuli 4A:
removing P2 from the Asp residue of the compound of formula III to form eptifibatide. 
(EB i uklanjanje P, iz Asp ostatka spoja formule III da nastane eptifibatid.
The device according to claim 1, wherein the endothelial lid comprises a notch that allows passing a microscope objective or any other instrument that needs to be close to the cornea for analysis or treatment of the cornea through the device. The device according to claim 1, wherein the overpressure is equal to the physiological intra-ocular pressure. 
Uređaj (1) u skladu s patentnim zahtjevom 1, naznačen time što poklopac za endotel (4) sadrži usjek koji omogućuje prolaženje objektiva mikroskopa ili bilo kojeg drugog instrumenta koji treba biti bliže rožnici i namijenjen je analizi ili obradi rožnice kroz uređaj.
A compound having the following structure: 
je C;.4 alkilna skupina.
demodulating the received signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; 
sredstva za demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM);
The product for use according to claim 15 wherein the disease is fibromatosis. 
Proizvod za uporabu u skladu s patentnim zahtjevom 15, naznačen time da je bolest fibromatoza.
The composition of claim 3 wherein the surfactant is d-a-tocopheryl polyethylene glycol 1000 succinate, poloxamer 188, or a mixture of any two or more thereof. 
Sastav prema patentnom zahtjevu 3. naznačen time, da površinski aktivna tvar jest d-a-tokoferil polictilen glikol 1000 sukcinat, poloksamer 188, ili smjesa od bilo kojeg od dvoje ili od više njih.
A compound, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, according to any of claims 1-11 for use in treating, preventing, and/or delaying the onset of a pathology selected from: Alzheimer's disease, Down's syndrome, Parkinson's disease, stroke, microgliosis, brain inflammation, pre-senile dementia, senile dementia, progressive supranuclear palsy, cortical basal degeneration, olfactory impairment associated with Alzheimer's disease, Parkinson's disease, and/or Down's syndrome, B-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, mild cognitive impairment glaucoma, amyloidosis, type II diabetes, diabetes-associated amyloidogenesis, scrapie, bovine spongiform encephalitis, Creutzfeld-Jakob disease, and traumatic brain injury. 
Spoj, ili njegov tautomer, ili farmaceutski prihvatljiva sol spomenutog spoja ili spomenutog tautomera prema bilo kojem od zahtjeva 1-11, naznačeni time, što se koriste za liječenje, prevenciju i/ili odgađanje pojave patologije koja se bira između: Alzheimer-ove bolesti, Down-ovog sindroma, Parkinson-ove bolesti, moždanog udara, mikroglioze, upale mozga, presenilne demencije, senilne demencije, progresivne supranukleusne paralize, kortikalne bazalne degeneracije, poremećaja čula mirisa udruženog sa Alzheimer-ovom bolešću, Parkinson-ovom bolešću, i/ili Down-ovim sindromom, B-amiloidne angiopatije, cerebralne amiloidne angiopatije, hereditarne cerebralne hemoragije, blagog kognitivnog poremećaja, glaukoma, amiloidoze, dijabetesa tipa II, amiloidogeneze udružene sa dijabetesom, šuge, goveđeg spongiformnog encefalitisa, Creutzfeld-Jakob-ove bolesti i traumatske povrede mozga.
The polypeptide of claim 1, wherein the soluble TNF superfamily cytokine domain is selected from soluble CD95 ligand (CD95L) or TNF-related apoptosis-inducing ligand (TRAIL) domains. 
(v) treću topljivu citokinsku domenu iz TNF obitelji, pri čemu se fuzijski polipeptid znatno ne agregira 1 pri čemu je topljiva citokinska domena iz TNF obitelji izabrana od topljivih TRAIL domena.
70% to 95% by weight of microcrystalline cellulose based on the total weight of said pharmaceutical dosage form. 
najmanje 30 masenih % mikrokristalne celuloze na osnovi ukupne mase navedenog farmaceutskog doznog oblika.
Vitamins: US 2003/0096414 (Ciccarone et al.) or U.S. Pat. No. 5,811,299 (Renner et al.) for example describe that the following vitamins may be used in a cell culture medium: Biotin, Pantothenate, Choline Chloride, Folic Acid, Myo-Inositol, Niacinamide, Pyridoxine, Riboflavin, Vitamin B12, Thiamine, Putrescine. 
- - vitamini: US 2003/0096414 (Ciccarone et al.) ili US 5,811,299 (Renner et al.) za primjer opisuju da slijedeći vitamini mogu biti korišteni u mediju za kulturu stanica: biotin, pantotenat, kolin klorid, folna kiselina, mioinozitol, niacinamid, piridoksin, riboflavin, vitamin BI2, tiamin, putrescin.
The nutritional composition according to claim 1, wherein the lipids provide 30 to 60% of the total calories, the protein provides 5 to 20% of the total calories and the digestible carbohydrates provide 25 to 75% of the total calories. 
9. Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje lipidi daju 30 do 60 % ukupnih kalorija, proteini daju 5 do 20% ukupnih kalorija i probavljivi ugljikohidrati daju 25 do 75% ukupnih kalorija.
wherein the binding protein binds human CD37. A humanized or chimeric CD37-specific immunoglobulin binding protein, comprising: a light chain variable region comprising, from amino terminus to carboxy terminus, a first framework region, a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 61, a second framework region, a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 64, a third framework region, a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 66, and a fourth framework region; and 
humane okvirne regije lakog lanca, laki lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:61, laki lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:64 i laki lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO:66, i humane okvirne regije teškog lanca, teški lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:63, teški lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:65 i teški lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO: 67 ili 68.
A process for the purification of water, wherein a surface-reacted natural calcium carbonate is brought into contact with the water to be purified, the surface-reacted natural calcium carbonate being the reaction product of a natural calcium carbonate with an acid and carbon dioxide, which is formed in situ by the acid treatment and/or supplied externally, and the surface-reacted natural calcium carbonate being prepared as an aqueous suspension having a pH of greater than 6.0, measured at 20°C, and a polymeric flocculant is added to the water to be purified subsequent to the addition of the surface-reacted natural calcium carbonate. 
HR P20140734 T1 PATENTNI ZAHTJEVI Postupak za pročišćavanje vode, gdje se površinski-reagirani prirodni kalcij karbonat dovodi u kontakt sa vodom koju se treba pročistiti, pri čemu je površinski-reagirani prirodni kalcij karbonat produkt reakcije prirodnog kalcij karbonata sa kiselinom i ugljičnim dioksidom, koji je stvoren in situ pomoću tretmana kiselinom i/ili uveden izvana, te se površinski-reagirani prirodni kalcij karbonat priprema kao vodena suspenzija sa pH većim od 6.0, mjereno pri 20%C, te se dodaje polimerni flokulant u vodu koju se treba pročistiti nakon dodatka površinski-reagiranog prirodnog kalcij karbonata.
is the linker connected to the anti-DLL3 antibody; 
M obuhvaća protutijelo anti-DLL3 koje se specifično veže na epitop unutar
A medicinal cream for topical treatment of bacterial infections and for wound healing, said cream containing Fusidic acid and a biopolymer, preferably chitosan, wherein said fusidic acid is made in situ under oxygen- free environment using Sodium Fusidate, wherein said cream comprises Fusidic acid made in situ by a conversion of Sodium Fusidate, and a biopolymer provided in a cream base, said cream base containing at least one of each of a primary and secondary emulsifier, a waxy material, a co-solvents, an acid, and water. 
Medicinska krema za topično liječenje bakterijskih infekcija 1 za zacjeljivanje rana, kod čega navedena krema sadrži fusidinsku kiselinu i biopolimer, prvenstveno Kitosan, naznačena time, da se navedena fusidinska kiselina priprema na licu mjesta u okolini bez kisika, koristeći natrijev fusidat, kod čega navedena krema sadrži fusidinsku kliselinu pripremljenu na licu mjesta konverzijom natrijevog fusidata, te biopolimer dan u bazi kreme, koja navedena baza kreme sadrži barem jedan od svakog od primarnih i sekundarnih emulgatora, voštanu tvar, te ko-otapala, kiselinu i vodu.
The pharmaceutical composition according to claim 1, comprising said 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and said excipient in a ratio of about 1:8 by weight. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time da sadrži navedenu 1-[3-(4-bromo-2-metil-2H- pirazol-3-il)-4-metoksi-fenil]-3-(2,4-difluoro-fenil)-ureu i navedenu pomoćnu tvar u omjeru od oko 1:8 po masi.
G represents a phenyl group or a 5- or 6-membered heteroaryl group having, in the ring, 1 to 3 heteroatoms independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, wherein the 5-membered heteroaryl group optionally has 1 or 2 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a dihalo-C1-C6 alkyl group, and a trihalo-C1-C6 alkyl group, and the phenyl group and the 6-membered heteroaryl group each optionally have 1 to 3 substituents independently selected from the group consisting of a 5- or 6-membered heteroaryl group having, in the ring, 1 to 3 heteroatoms independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, a halogen atom, a cyano group, a C1-C6 alkyl group, a C1-C6 alkoxy group, and a trihalo-C1-C6 alkyl group; 
G predstavlja fenil grupu ili 5-očlanu ili 6-očlanu heteroaril grupu koja ima, u prstenu, 1 do 3 heteroatoma koji su nezavisno odabrani od grupe koja se sastoji od atoma dušika, atoma kisika, i atoma sumpora, gdje 5-očlana heteroaril grupa po izboru ima 1 ili 2 supstituenta nezavisno odabranih od grupe koja se sastoji od atoma halogena, cijano grupe, C,-Cx alkil grupe, Cy-C4 alkoksi grupe, dihalo-C,-C4 alkil grupe, i trihalo-C,-C; alk1l grupe, i fenil grupu i 6-očlanu heteroaril grupu pri čemu svaka po izboru ima 1 do 3 supstituenata nezavisno odabranih od grupe koja se sastoji od 5-očlane ili 6-očlane heteroaril grupe koja ima, u prstenu, 1 do 3 heteroatoma nezavisno odabranih od grupe koja se sastoji od atoma dušika, atoma kisika, i atoma sumpora, atoma halogena, cijano grupe, Ci-C4 alkil grupe, Cy-C4 alkoksi grupe, i trihalo-Cy-Cg alkil grupe;
The animal of claim 1, wherein the first nucleotide sequence is located at the endogenous non-human MHC I locus, the second nucleotide sequence is located at the endogenous non-human MHC II a locus, and the third nucleotide sequence is located at the endogenous non-human MHC II B locus. 
Životinja prema zahtjevu 1, naznačena time, da se prva nukleotidna sekvenca nalazi na endogenom ne-humanom MHC-I-lokusu, druga nukleotidna sekvenca se nalazi na endogenom ne-humanom MHC-II-a-lokusu, a treća nukleotidna sekvenca se nalazi na endogenom ne-humanom MHC-II-B-lokusu.